Auxly Cannabis Group Inc.
TSX:XLY.TO · Toronto Stock Exchange
+$0.00 today
Vol 3.79M · Avg 0.71M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
TSX:XLY.TO · Revenue to Net Income
Key Ratios
Analysis
$158.6M of revenue converted into $33.2M of net income for the selected period. Gross margin is 47.6% and net margin is 21.0%, showing how much revenue survives after costs and taxes. EPS is $0.02, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $151.5M +23.8% | $122.3M +21.0% | $101.1M +7.0% | $94.5M +12.7% | $83.8M | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $64.7M +3.7% | $62.4M -21.8% | $79.8M +2.4% | $78.0M +20.8% | $64.5M | $725.6M | $804.0M | $882.4M |
| Gross Profit | $86.7M +44.7% | $59.9M +181.7% | $21.3M +28.9% | $16.5M -14.4% | $19.3M | $8.9B | $7.6B | $6.2B |
| Gross Margin | 57.3% +8.3pp | 49.0% +27.9pp | 21.1% +3.6pp | 17.5% -5.5pp | 23.0% | 9.8% | 28.9% | 38.3% |
| Research & Development | $0 | $0 -100.0% | $497.0K +70.2% | $292.0K -2.0% | $298.0K | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $49.1M +20.5% | $40.7M +1.1% | $40.3M -20.0% | $50.4M +10.9% | $45.4M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $54.1M +19.6% | $45.2M -4.3% | $47.2M -27.9% | $65.5M +12.5% | $58.2M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $11.4M +11.4% | $10.3M -8.3% | $11.2M -44.5% | $20.2M +41.4% | $14.3M | $374.2M | $1.2B | $631.8M |
| EBITDA | $50.3M +106.4% | $24.4M +323.8% | -$10.9M +88.5% | -$94.8M -418.0% | -$18.3M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | 33.2% +13.3pp | 19.9% +30.7pp | -10.8% +89.6pp | -100.3% -78.5pp | -21.8% | 5.6% | 46.3% | 42.0% |
| Operating Income | $32.7M +122.0% | $14.7M +156.7% | -$25.9M +47.0% | -$49.0M -25.8% | -$38.9M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | 21.6% +9.5pp | 12.0% +37.7pp | -25.7% +26.2pp | -51.8% -5.4pp | -46.4% | 16.6% | 24.1% | 22.0% |
| Interest Income | $130.0K -45.8% | $240.0K +650.0% | $32.0K -90.5% | $337.0K -78.8% | $1.6M | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $6.3M -56.1% | $14.5M -43.6% | $25.7M +18.9% | $21.6M +22.1% | $17.7M | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | -$155.0K +99.0% | -$15.1M +30.9% | -$21.8M +75.1% | -$87.6M -674.9% | -$11.3M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | $32.5M +9234.0% | -$356.0K +99.3% | -$47.7M +65.0% | -$136.6M -171.8% | -$50.2M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | 21.5% +21.8pp | -0.3% +46.9pp | -47.2% +97.3pp | -144.5% -84.6pp | -59.9% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | -$9.3M -158.4% | $16.0M +593.9% | -$3.2M +48.3% | -$6.3M -44.6% | -$4.3M | $1.3B | -$1.6B | $745.2M |
| Net Income | $41.9M +356.0% | -$16.3M +63.3% | -$44.5M +65.8% | -$130.3M -286.2% | -$33.7M | $4.9B | $4.8B | $4.7B |
| Net Margin | 27.6% +41.0pp | -13.4% +30.7pp | -44.0% +93.9pp | -137.9% -97.7pp | -40.2% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | $0 +331.6% | -$0 +69.7% | -$0 +70.1% | -$0 -156.0% | -$0 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | $0 +294.1% | -$0 +69.7% | -$0 +70.1% | -$0 -156.0% | -$0 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $1.3B +10.4% | $1.2B +21.6% | $991.0M +11.4% | $889.9M +13.6% | $783.4M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $1.6B +31.7% | $1.2B +21.6% | $991.0M +11.4% | $889.9M +13.6% | $783.4M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
NervGen Pharma Corp.
NGEN.V
$407.94M
CareRx Corporation
TSX:CRRX.TO
$203.03M
Cannara Biotech Inc.
LOVE.V
$181.03M
Cardiol Therapeutics Inc.
TSX:CRDL.TO
$171.76M
BioSyent Inc.
RX.V
$160.48M
Cybin Inc.
CYBN.NE
$157.82M
Grown Rogue International Inc.
GRIN.CN
$149.96M
HLS Therapeutics Inc.
TSX:HLS.TO
$133.86M
Jushi Holdings Inc.
JUSH.CN
$133.80M
Decibel Cannabis Company Inc.
DB.V
$69.23M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does XLY.TO generate?
Auxly Cannabis Group Inc. (XLY.TO) reported $151.48M of revenue in fiscal 2025.
Is XLY.TO profitable?
Auxly Cannabis Group Inc. (XLY.TO) reported $41.85M of net income, with a net margin of 27.6%.
Explore More
Continue the stock analysis
Jump to another research area for this company.